Consulta: subjectFacets:"Interferon-alpha"
Registros recuperados: 7
Data/hora: 06/06/2024 03:16:51

Are anti-interferon antibodies the cause of failure in: chronic HCV hepatitis treatment?
Provedor de dados: 55
Autores: Barone,Antonio Alci; Tosta,Rose Aparecida Borges; Tengan,Fátima Mitiko; Marins,José Humberto Caetano; Cavalheiro,Norma de Paula; Cardi,Bruno Andrade.
A follow-up study was made of 94 chronic hepatitis C patients at a hepatitis clinic in Brazil, after interferon alpha (IFN-alpha) therapy, to determine the influence of anti-interferon antibodies on treatment outcome. Patients diagnosed as having chronic hepatitis C, confirmed by PCR (HCV RNA) and liver biopsy, were treated with interferon alpha 2a or 2b for at least six months, and were followed up for 24 weeks after termination of treatment in order to assess biochemical, virological and clinical pathology responses. Only 6% of the 94 patients developed anti-IFN antibodies, 70% presented a biochemical response and 23% maintained a sustained virological response. Clinical evaluation revealed that in only 2 patients was there progression of fibrosis; the...
Tipo: Info:eu-repo/semantics/article
Palavras-chave: Interferon-alpha; Antibodies; Chronic HCV; Treatment.
Ano: 2004
URL: http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1413-86702004000100002

Thyroid disorders in patients with chronic hepatitis C using interferon-alpha and ribavirin therapy
Provedor de dados: 55
Autores: Andrade,Luis Jesuino de Oliveira; Atta,Ajax Mercês; Atta,Maria Luiza Brito de Sousa; Mangabeira,Célia Neder Kalil; Paraná,Raymundo.
OBJECTIVE: To investigate the frequency of thyroid disorders (TD) in patients with chronic hepatitis C before and during interferon-alpha (IFN-α) and ribavirin (RIB) treatment. STUDY DESIGN: Prospective study. PATIENTS AND METHODS: We prospectively studied 65 anti-HCV and viral RNA positive patients. Free thyroxine, thyroid-stimulating hormone, and thyroid peroxidase antibodies (TPO-Ab) were systematically tested at entry (m0), week 12 (m3) and week 24 (m6) of treatment. RESULTS: Mean age of the 65 patients (38 females and 27 males) was 49.61 ± 11.83 years. Seven (10.76%) patients presented baseline thyroid disorders (m0), three had thyroid dysfunction, and four were TPO-Ab positive. Thyroid disorders occurred in the first 12 weeks of treatment in 11...
Tipo: Info:eu-repo/semantics/other
Palavras-chave: Hepatitis C; Interferon-alpha; Ribavirin; Thyroid diseases; Autoimmunity.
Ano: 2011
URL: http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1413-86702011000400013

Pegylated interferon/ribavirin-associated sudden hearing loss in a patient with chronic hepatitis C in Brazil
Provedor de dados: 55
Autores: Mendes-Corrêa,Maria Cassia Jacintho; Bittar,Roseli Saraiva Moreira; Salmito,Norma; Oiticica,Jeanne.
Sudden hearing loss is defined as a sensorineural hearing loss, equal to or greater than 30 dB, at three or more consecutive frequencies, which takes place within 72 hours. Both peginterferon and ribavirin are well-known to be associated with significant adverse effects, but sudden hearing loss is uncommon. We report a 65-year-old male patient who developed sudden-onset hearing loss during combination therapy with pegylated interferon-alpha and ribavirin for chronic hepatitis C. Peginterferon and ribavirin may cause sudden hearing loss that may not recover after discontinuation of therapy. Immediate treatment for all possible etiologies is essential, along with targeted investigations and early referral for an Ear, Nose and Throat specialist. Physicians...
Tipo: Info:eu-repo/semantics/report
Palavras-chave: Hepatitis C; Chronic; Hearing loss; Sudden; Interferon-alpha.
Ano: 2011
URL: http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1413-86702011000100017

Psychosis during peginterferon-alpha2a and ribavirin therapy: case report
Provedor de dados: 55
Autores: Quarantini,Lucas C.; Cruz,Simone Cunha; Batista-Neves,Susana Carolina; Paraná,Raymundo; Miranda-Scippa,Ângela; Bressan,Rodrigo A.
Pegylated Interferon-alpha, combined with ribavirin, gives high sustained virological response in patients with hepatitis C virus, an important public health problem and one of the most frequent chronic infectious diseases worldwide. Though it has therapeutic benefits, treatment with IFN-alpha may be complicated by various side effects, especially symptoms of major depression and acute mania. Psychosis is a rare side effect, and its management usually includes discontinuation of IFN-alpha. We report a case of psychotic disorder that occurred during therapy with pegylated Interferon-alpha given associated with ribavirin. After good response to psychiatric treatment, it became possible to finish the anti-viral therapy.
Tipo: Info:eu-repo/semantics/report
Palavras-chave: Interferon-alpha; Hepatitis C; Psychosis.
Ano: 2006
URL: http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1413-86702006000600010

Clinical management of a patient with drug dependence who attempted suicide while receiving peginterferon therapy for chronic hepatitis C
Provedor de dados: 55
Autores: Fábregas,Bruno Cópio; Moura,Alexandre Sampaio; Marciano,Renata Cristiane; Carmo,Ricardo Andrade; Teixeira,Antônio Lúcio.
Pegylated interferon-alpha combined with ribavirin is the current gold standard treatment for chronic hepatitis C. Illicit drug dependence is not a rare co-morbidity among chronic hepatitis C population, what can make antiviral treatment an outmost challenge. Despite high sustained virological response rate following antiviral treatment, serious psychiatric adverse reactions may occur, like depression and suicide attempt. We report a patient with recurrent depressive disorder, previous history of suicide attempt and illicit drug dependence. We discuss the singularities and challenges of managing this patient in order to complete the antiviral treatment.
Tipo: Info:eu-repo/semantics/report
Palavras-chave: Interferon-alpha; Chronic hepatitis C; Depression; Suicide attempt; Drug addiction.
Ano: 2009
URL: http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1413-86702009000500015

Thyroid dysfunction in hepatitis C individuals treated with interferon-alpha and ribavirin: a review
Provedor de dados: 55
Autores: Andrade,Luis Jesuíno de Oliveira; Atta,Ajax Mercês; D'Almeida Junior,Argemiro; Paraná,Raymundo.
Hepatitis C (HCV) is now the main cause of chronic hepatic disease, cirrhosis and hepatocellular carcinoma. Several extrahepatic diseases have been associated with chronic HCV infection, and in most cases appear to be directly related to the viral infection. Thyroid disorders are common in patients with chronic HCV. Some patients with chronic hepatitis C experience thyroid problems, and thyroid dysfunction may also be a side effect of interferon-based treatment. The principal risk factor for developing thyroid disease in the course of antiviral therapy is the previous positivity for anti-thyroid antibodies (anti-thyroid peroxidase) especially in older women. Screening for autoantibodies and serum thyroid-stimulating hormone is recommended before, during...
Tipo: Info:eu-repo/semantics/article
Palavras-chave: Hepatitis C; Interferon-alpha; Ribavirin; Thyroid dysfunction; Thyroiditis.
Ano: 2008
URL: http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1413-86702008000200009

Soluble inflammatory markers as predictors of hepatocellular damage and therapeutic response in chronic hepatitis C
Provedor de dados: 55
Autores: Moura,Alexandre Sampaio; Carmo,Ricardo Andrade; Teixeira,Antonio Lucio; Rocha,Manoel Otávio da Costa.
Hepatitis C is an important burden worldwide being an important cause of cirrhosis and liver cancer in different parts of the world. Host immune response, especially T helper type 1 (Th1) cell-mediated, seems to play an important role in disease progression but is also crucial for viral elimination following specific therapy. Immune activation can be evaluated using peripheral levels of different cytokines, such as different chemokines (e.g. CCL5, CXCL10) and tumor necrosis factor alpha (TNF-α), and their soluble receptors (e.g. soluble TNF-α receptors 1 (sTNF-R1) and 2 (sTNF-R2). This review article focuses on the potential use of peripheral inflammatory markers as predictors of liver histological changes and therapeutic response among patients with...
Tipo: Info:eu-repo/semantics/article
Palavras-chave: Hepatitis C; Chemokines; Tumor necrosis factor receptor; Interferon-alpha; Liver fibrosis.
Ano: 2009
URL: http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1413-86702009000500013